39 results about "Oral gavage" patented technology

Methods, compositions and devices are provided by the present invention for reducing activity of a natriuretic peptide receptor and other signals. Therapeutic treatments are provided by use of polynucleotides encoding a natriuretic peptide or by regulating the expression of natriuretic peptide receptor, such as NPRA and NPRC, or combinations of these therapies. Routes used for delivering polynucleotides encoding a natriuretic peptide, or, for example, siRNA that down regulates natriuretic peptide receptor include subcutaneous injection, oral gavage, transdermal and intranasal delivery routes. Compositions can include chitosan, chitosan derivatives, and chitosan derivative and a lipid. Transdermal delivery can use a transdermal cream. Intranasal delivery can use a dropper or an aspirator for delivery of a mist. Oral gavage delivers equivalent to oral delivery. Delivery permits cell and tissue specific targeting of gene therapies resulting in expression of a natriuretic peptide or down regulation of natriuretic peptide receptor. A variety of cancers, asthma and viral diseases can be treated therapeutically using the methods and compositions of the present invention.

The invention discloses a sodium aescinate micro-emulsion injection. The formula of the sodium aescinate micro-emulsion injection comprises sodium aescinate, an oil phase, a surfactant and a cosurfactant. Compared with the oral gavage, the sodium aescinate micro-emulsion injection for intravenous injection provided by the invention has the advantages that the bioavailability is high, the concentration of the injection in the liver can be increased obviously, the concentration of the injection in the kidney can be reduced, meanwhile, the irritation on the wall of the blood vessel is alleviated, and the generation times of phlebophlogosis can be reduced, so that the curative effect is improved, and the toxic and side effect is lowered.

A nutritional composition for gastrostomy-tube patients who are at an increased development risk of aspiration pneumonia and require careful risk management, which can be more safely consumed by gastrostomy-tube patients while suppressing the development of aspiration pneumonia, is administered to those patients who require risk management for aspiration pneumonia, and contains a protein source, a carbohydrate source, and a lipid source, the protein source including only amino acids.

The invention discloses recombinant lactococcus lactis based on the fbsA gene of Streptococcus agalactiae. The recombinant lactococcus lactis comprises the fbsA gene of Streptococcus agalactiae or segments of the fbsA gene, the fbsA gene or the segments of the fbsA gene preferably has (or have) a sequence shown in SEQ ID No. 1, the deposit number of the recombinant lactococcus lactis is CCTCC M 2020140, and expression of recombinant FbsA protein with a theoretical molecular weight of 34.6 kDa can be induced under the culture condition that niusin exists. The invention also provides a vaccine for the Streptococcus agalactiae disease of Oreochromis sp., and the vaccine is prepared from the recombinant lactococcus lactis, and is capable of producing protective antibodies in Oreochromis sp. after Oreochromis sp. is fed with the vaccine in an immune mode of oral gavage, so that Oreochromis sp. is assisted to resist infection of Streptococcus agalactiae effectively.

The invention discloses a bacterial ghost preparation method of an independent lysis gene E. According to the preparation method, a bacterium suspension solution is added with four chemical substances including NaOH, Triton X-100, Na2EDTA and H2O2 to prepare the bacterial ghost in order to satisfy the requirements of complete release of bacterium content and completeness of a bacterium ghost. The method is simple and rapid to operate; except lysis holes, the cell shape and surface structure of the prepared bacterial ghost are not obviously changed. The bacterial ghost prepared by the method disclosed by the invention can enter a specific cell in a targeted manner, is free of toxicity to the cell and can be used as a novel transferring carrier for a drug. The bacterial ghost prepared by the method disclosed by the invention can also be used for immunizing a BALB/c mouse by intraperitoneal injection or oral gavage, also has quite good protection efficiency to homologous counteracting toxic substances and can be used as a novel vaccine.

The invention relates to the industries of functional food and medicine, in particular to a glucosamine chondroitin sulfate salt as well as a preparation method and application thereof. The structuralformula of the glucosamine chondroitin sulfate salt is shown as a formula (1), and the value range of the average polymerization degree n is 5-1000. The glucosamine chondroitin sulfate salt is obtained by performing ion exchange on glucosamine hydrochloride or sulfate or phosphate and chondroitin sulfate sodium, or dialyzing with a mixed solution, or directly precipitating with the mixed solution, , the molecular weights of chondroitin sulfates are all polysaccharides which are obtained through natural extraction, fermentation preparation or degradation, or a synthesis method and accord withthe chondroitin sulfate structures. The chondroitin sulfate and glucosamine are organically combined together, the glucosamine chondroitin sulfate salt is different from an existing compound product of the chondroitin sulfate and the glucosamine, the glucosamine chondroitin sulfate salt does not contain micromolecular inorganic salts or is very low in content of the micromolecular inorganic salts,and the prepared glucosamine chondroitin sulfate salt has a good treatment effect on osteoarthritis model rats in an oral gavage mode; the micromolecular inorganic salts be used for but not limited to joint treatment or auxiliary health care. The glucosamine chondroitin sulfate salt can be widely applied to the fields of functional foods and medicines.

We report for the first time that pterostilbene, a natural analog of resveratrol, shows anxiolytic-like action by downregulating phosphorylated levels of ERKs in the hippocampus of mice. Mice administered pterostilbene (1-10 mg/kg BW) by oral gavage were subjected to the Elevated-plus maze (EPM) test. Pterostilbene manifested anxiolytic activity at 1 and 2 mg/kg doses, demonstrated by an increase in percent permanence time and number of entries in open arms, critical determinants correlated with anxiety. This anxiolytic activity of pterostilbene was comparable to that of diazepam at 1 and 2 mg/kg in the EPM. The percent traveled distance and the percent permanence time in the enclosed arms were decreased with the 1 and 2 mg/kg doses. The 5 and 10 mg/kg doses did not show any anxiolytic effect. Locomotor activity was unaffected in all doses. Western blot analysis corroborated the observed behaviors in the EPM, revealing a decrease in both ERK1 and ERK2 phosphorylation in hippocampal homogenates from mice treated with 1 and 2 mg/kg doses; the 5 and 10 mg/kg doses showed no significant effect on the phosphorylation of ERKs. Pterostilbene was detected in serum and brain tissue following a single oral administration, demonstrating that the compound can cross the blood-brain barrier to reach the brain regions, including hippocampus, and thereby exert its anxiolytic effect. Resveratrol, the parent molecule of pterostilbene, did not have any anxiolytic effect.

The invention discloses a test method of developmental toxicity of silkworms by environmental estrogen. The method includes following steps: firstly, injecting a test sample containing a series of concentrations to 5-age silkworm larvae through 2-hour starvation treatment by employing oral gavage; after 20 minutes, performing anatomy on the silkworms through gavage, and taking tissues and organs;determining the developmental toxicity of the silkworms by the test sample through comparison of toxic endpoints of an infected group and a control group, wherein the toxic endpoints comprise a glutathione reductase activity coefficient and an anti-superoxide anion free radical activity of midguts of the silkworms; and researching the influence of the environmental estrogen 4-nonylphenol on the development of the midguts of the silkworms in a larva stage to determine a dose-effect relation between the environmental estrogen and the developmental toxicity of the silkworms in the larva stage. Byemploying the technical scheme, multiple biological effect endpoints can be generated for the environmental estrogen nonylphenol, potential risks of the silkworms exposed in an estrogen environmentalconcentration level are evaluated, and the method is a relatively fast, simple and sensitive detection method.

The invention relates to application of demethylwedelolactone-7-sulphate in preparation of an anti-pulmonary fibrosis medicine. The compound demethylwedelolactone-7-sulphate is obtained from a traditional Chinese medicinal material eclipta for the first time, and the structure is determined by virtue of NMR (nuclear magnetic resonance) and other spectrum data; In-vivo and in-vitro pharmacological experiment results prove that the demethylwedelolactone-7-sulphate can be used for remarkably inhibiting proliferation of TGF (transforming growth factor)-beta1 induced human embryonic lung fibroblast and HYP (hydroxyproline) content thereof, and inflammation and fibrosis degree of the lung tissue in a bleomycin induced mouse pulmonary fibrosis model can be improved in the oral gavage dosing range of 5-30mg/kg, the MDA (methylene dioxyamphetamine) content reflecting the lung injury degree in the lung tissue can be influenced, the HYP content reflecting lung tissue collagen deposition can be reduced, and the cytokine TGF-beta1 content causing pulmonary fibrosis can be reduced, so that the pharmacological action of the pulmonary fibrosis degree can be improved. The demethylwedelolactone-7-sulphate has novel application in medicines for treating or improving pulmonary fibrosis diseases.

Disclosed are an oxygen humidifying liquid bag and an oxygen humidifying device. The oxygen humidifying liquid bag comprises a bag body and a mouth tube component; the mouth tube component is connected to the bag body in a sealed mode; the mouth tube component is provided with an internal channel communicating with an inner cavity of the humidifying liquid bag; an inner cavity of the humidifying liquid bag is used for containing humidifying liquid; the internal channel of the mouth tube component is provided with a humidifying liquid outlet; the humidifying liquid bag further comprises a slender humidifying liquid conveying channel extending to the lower portion of the humidifying liquid bag body; the upper portion of the humidifying liquid conveying channel communicates with the internal channel of the mouth tube component; the humidifying liquid conveying channel is provided with at least one lower opening; the lower opening of the humidifying liquid conveying channel communicates with the inner cavity of the humidifying liquid bag; the oxygen humidifying device comprises a container with an oxygen inlet structure and an oxygen outlet structure; a part or all of an inner cavity of the container can be used for humidifying oxygen; the oxygen humidifying device further comprises a humidifying liquid pump and an oxygen humidifying liquid bag connecting structure; humidifying liquid is sucked into the humidifying liquid pump through the humidifying liquid outlet via the connecting structure; and the humidifying liquid enters the inner cavity of the container through a pump outlet structure of the humidifying liquid pump.

The invention discloses an ophthalmic nursing liquid medicine dripping device and a mounting and using method thereof, and relates to the technical field of ophthalmic nursing. An eyelid pressing silica gel plate is extruded and clamped into a fixed clamping plate; a propelling and dripping assembly is slidably mounted on a handheld rod, the upper side of a sliding body is fixedly connected with an extended fixed pipe, and a dripping pipe head is communicated with an upstream connector pipe; a liquid guide fixing assembly is fixedly mounted at the other side end of the handheld rod, the liquid guide fixing assembly comprises a fixed mounting piece fixedly connected with the handheld rod in a matched mode, a downstream liquid conveying opening pipe is arranged on the bottom side of the fixed mounting piece, and one end of the fixed mounting piece is connected with an end mounting cover body; the end mounting cover body comprises an end mounting groove and an injection port positioned at the bottom of the end mounting groove, the injection port is communicated with the downstream liquid conveying opening pipe, and the end mounting cover body is in threaded connection with a bag-shaped tail bottle; and the handheld rod is provided with a strip-shaped through slot. Eyedrops can be correctly dropped, and the intense foreign body sensation of an eyedrops bottle or a dropping device to the eyes when the eyedrops are dropped is also reduced.

An improved nasal cannula is provided. Some illustrative embodiments are a cannula comprising a first nasal tube having a device end and an aperture end (wherein the cannula is configured to place the aperture end in fluid communication with the first naris of a patient), a second nasal tubing having a device end and an aperture end (wherein the cannula is configured to place the aperture end of the second nasal tubing in fluid communication with a second naris of the patient), and an oral tubing having a device end and an aperture end, and the oral tubing mechanically coupled to at least one of the first or second nasal tubing (wherein the cannula is configured to place the aperture end of the oral tubing in fluid communication with the mouth of a patient). The first nasal tubing, the second nasal tubing and the oral tubing are fluidly independent between their aperture ends and their device ends.